NCT02446795 - Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions

Renal Cell CarcinomaKidney Cancer

Interventions

DRUG

Sunitinib

Sunitinib: 50mg once daily orally for 4 weeks followed by 2 weeks off treatment (either at 8 a.m. or at 8 p.m.)

DRUG

Isoquercetin

Isoquercetin: 225mg twice a day(at 08 a.m. and at 4 p.m)/Isoquercetin: 450 mg twice a day(at 08 a.m. and at 4 p.m).

DRUG

Placebo

Placebo: 225mg twice a day(at 08 a.m. and at 4 p.m)/Placebo: 450 mg twice a day(at 08 a.m. and at 4 p.m).

Trial Locations (5)

NOT_YET_RECRUITING

Azienda Ospedaliera Cardarelli Divisione Di Oncologia, Napoli

NOT_YET_RECRUITING

Ospedale Oncologico Regionale - Centro di Riferimento Oncologico di Basilicata U.O. di Oncologia Medica, Rionero in Vulture

NOT_YET_RECRUITING

Fondazione G. Pascale, Naples

RECRUITING

University Federico II of Naples, Naples

NOT_YET_RECRUITING

Azienda Ospedaliera Ruggi Aragona, Salerno